Abstract
Changes in phenytoin concentrations caused by switching valproate formulations with different absorption rates were retrospectively investigated in eleven epileptic patients receiving treatment with both drugs. Total plasma phenytoin concentrations were measured before and after a standard tablet of valproate was replaced by the same dose as a slow-release tablet.
The mean plasma phenytoin level rose significantly from 14.4 to 18.7 μg·ml−1. Nine of eleven patients had markedly increased phenytoin levels (by 21 to 72%), and two developed toxic symptoms.
The results indicate that changing valproate formulations can cause major alterations in the plasma concentration of co-administered phenytoin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bourgeois BFD (1988) Pharmacologic interactions between valproate and other drugs. Am J Med 84 [Suppl 1A]: 29–33
Bruni J, Wilder BJ, Willmore LJ, Barbour B (1979) Valproic acid and plasma levels of phenytoin. Neurology 29: 904–905
Bruni J, Gallo JM, Lee CS, Perchalski RJ, Wilder BJ (1980) Interactions of valproic acid with phenytoin. Neurology 30: 1233–1236
Cramer JA, Mattson RH (1979) Valproic acid: in vitro plasma protein binding and interaction with phenytoin. Ther Drug Monit 1: 105–116
Cramer JA, Mattson RH, Bennett DM, Swick CT (1986) Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther Drug Monit 8: 411–415
Dodson WE (1988) Aspects of antiepileptic treatment in children. Epilepsia 29 [Suppl 3]: S10-S14
Fukushima K, Sagisaka M, Sue H, Terauchi N, Ishida S, Yagi K, Seino M (1988) A pharmacokinetic study and anti-epileptic effect of KW-6066N — A new slow-release form of valproate. Jpn J Neuropsychopharmacol 10: 711–721
Lai M-L, Huang J-D (1993) Dual effect of valproic acid on the pharmacokinetics of phenytoin. Biopharm Drug Dispos 14: 365–370
Monks A, Richens A (1980) Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Clin Pharmacol Ther 27: 89–95
Riva R, Albani F, Contin M, Perucca E, Ambrosetto G, Gobbi G, Santucci M, Procaccianti G, Baruzzi A (1985) Time-dependent interaction between phenytoin and valproic acid. Neurology 35: 510–515
Sallustio BC, Morris RG (1992) Unbound plasma phenytoin concentrations measured using enzyme immunoassay technique on the Cobas MIRA analyser-In vivo effect of valproic acid. Ther Drug Monit 14: 9–13
Suzuki Y, Cox S, Hayes J, Walson PD (1991) Valproic acid dosages necessary to maintain therapeutic concentrations in children. Ther Drug Monit 13: 314–317
Takeda A, Inaguma J, Simizu A, Terao S, Amioka K, Hishida H, Sakamoto Y (1988) Pharmacokinetic study of a slow-release preparation of sodium valproate (KW-6066N) — Single dose administration test and the effects of food on valproate absorption. J Jpn Epil Soc 6: 196–203
Takeda A, Hishida H, Amioka K, Sakamoto Y, Terao S, Ishikawa S, Aoki H (1989) Pharmacokinetic study of a slow-release preparation of sodium valproate (KW-6066N): multiple dose administration test and the steady-state serum level profiles in epileptic patients. Jpn J Psychiat Neurol 43: 515–516
Tatsuhara T, Muro H, Matsuda Y, Morita T, Amisaki T, Takeshita K (1988) Pharmacokinetics of valproic acid and its metabolites after a single oral administration of a sustained-release preparation of sodium valproate (KW-6066N). Jpn J Clin Pharmacol Ther 19: 749–757
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Suzuki, Y., Nagai, T., Mano, T. et al. Interaction between valproate formulation and phenytoin concentrations. Eur J Clin Pharmacol 48, 61–63 (1995). https://doi.org/10.1007/BF00202174
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00202174